Article

Floppy iris syndrome requires special care

Cincinnati—Tamsulosin HCl (Flomax, Boehringer Ingelheim), an alpha-1 blocker used to treat benign prostatic hyperplasia, has been implicated in the development of floppy iris syndrome during cataract surgery, according to Robert H. Osher, MD. Healon 5 (AMO) is his viscoadaptive agent (OVD) of choice to manage this challenging iris behavior during cataract surgery.

Dr. Osher recounted in an interview with Ophthalmology Times that at the American Academy of Ophthalmology (AAO) meeting in 2004, he and David F. Chang, MD, of Los Altos, CA, taught a course. Dr. Chang introduced a hypothesis that he and John R. Campbell, MD, of San Rafael, CA, developed about the behavior of an iris that is floppy and a medical history positive for prostate problems treated with tamsulosin HCl. To underscore the difficulty of these cases, Dr. Chang also reported a 12.5% complication rate of torn posterior capsules associated with the syndrome.

"I thought that this was a brilliant deductive exercise and one of the best bits of detective work that I have seen in ophthalmology," Dr. Osher said. He is professor of ophthalmology at the University of Cincinnati, and medical director emeritus of the Cincinnati Eye Institute.

"This prompted me to believe in the lethality of Flomax to the iris," he stated.

Use of tamsulosin HCl can result in poor dilation of the iris, which occurs because the drug is an alpha-1 blocker that affects the smooth muscle receptors throughout the body, Dr. Osher explained.

Tamsulosin HCl has become the favorite of urologists because other alpha-1 blockers, such as doxazosin mesylate (Cardura, Pfizer) and terazosin HCl (Hytrin, Abbott Laboratories), are less selective than tamsulosin HCl and increase the risk of postural hypotension.

In addition, the pupils of these patients are much more likely to constrict during surgery and the iris can billow and leap toward the aspiration port on the phaco handpiece or the irrigation/aspiration (I/A) handpiece because of its lack of tone.

The iris will also attempt to leap into the incision, even the stab incision, because of its sensitivity to a change in pressure gradient in the eye.

Dr. Osher initially tried to manage the floppy iris in these patients with the standard stretch technique of Luther L. Fry, MD, which he said he has always found to be effective for managing suboptimal pupils.

"However, in these cases, the Fry stretch technique not only does not work but also may be contraindicated because it further compromises the iris tone. When the OVD is injected after a stretch technique is performed, the pupil normally dilates beautifully. When the OVD is injected after the Fry stretch technique, the OVD almost blows out the iris. This is very paradoxical," he emphasized.

Dr. Chang had suggested the use of iris hooks or retractors for managing floppy iris syndrome in patients who had taken tamsulosin HCl. However, this option, although effective, is less than perfect because these devices take time to insert and can cause trauma to the iris, Dr. Osher noted.

There are pupil-dilating devices, similar to tires, on the market that are available from a number of companies. Use of these may require challenging manipulations, although they are effective. Drugs that have been attempted are intracameral phenylephrine, an idea introduced by Richard B. Packard, MD, who is in private practice in London and Windsor, England, and consultant ophthalmologist, Prince Charles Eye Unit, Windsor. Samuel Masket, MD, proposed using preoperative atropine, but this has met with mixed success, Dr. Osher noted. Even stopping tamsulosin HCl provides minimal, if any, benefit.

Notable attributes

Healon 5 possesses certain attributes that made Dr. Osher suspect that this OVD may be helpful in patients with floppy iris syndrome.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.